ENTA

Enanta Pharmaceuticals Inc.

Price

$13.51

return (12m)

61.03%

p/e

-5.95

p/bv

3.72

DIVIDEND YIELD

0.00%

ENTA price

Enanta Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ENTA

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

-2.31%

1 year

61.03%

2 years

6.97%

5 years

-73.67%

10 years

-43.02%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals ENTA

Valuation

P/E

-5.95

Sector -4.38

Industry -4.38

P/BV

3.72

Sector 2.02

Industry 2.02

P/Revenue (PSR)

5.76

Sector -4.40

Industry -4.40

EV/EBITDA

-13.18

Sector -263.09

Industry -263.09

EV/EBIT

-12.16

Sector -702.90

Industry -702.90

P/EBITDA

-8.30

Sector -4.39

Industry -4.39

P/EBIT

-7.49

Sector -4.73

Industry -4.73

P/Total Assets

1.27

Sector 1.49

Industry 1.49

P/Net Current Assets

48.08

Sector -11.70

Industry -11.70

P/Working Capital

2.52

Sector -3.19

Industry -3.19

EPS

-2.18

Sector -2.14

Industry -2.14

BVPS

3.49

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-98.54%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-106.82%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-90.01%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-96.90%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.05

Sector 0.03

Industry 0.03

Profitability

ROE

-62.56%

Sector -65.14%

Industry -65.14%

ROA

-21.30%

Sector -65.53%

Industry -65.53%

ROIC

-45.14%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

3.76

Sector 2.90

Industry 2.90

Net Debt / EBITDA

13.39

Sector -6.07

Industry -6.07

Net Debt / EBIT

12.35

Sector -8.26

Industry -8.26

Net Debt / Equity

-1.88

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.34

Sector 0.41

Industry 0.41

Liabilities/Assets

0.66

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-6.84%

Sector -

Industry -

5Y Earnings CAGR

-8.90%

Sector -

Industry -

Fundamentals ENTA

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ENTA Enanta Pharmaceuticals Inc.	$13.51	65.36%	0.00%	-5.95	3.72	-62.56%	-96.90%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ENTA Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Enanta Pharmaceuticals

Enanta Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (0 people)

United States

31 years

Founded: 1995

2013

Time since IPO - 13 years

141

Employees

Enanta Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $375.99 million, with shareholders equity totaling $101.07 million.

The company employs approximately 141 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Enanta Pharmaceuticals Inc. reported $65.25 million in revenue, generating net income of $-63.23 million.

Key financial metrics include a P/E ratio of -5.95, a price-to-book (P/B) ratio of 3.72, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ENTA.

Market cap

$375.99 million

Net worth

$101.07 million

$101,070,000.00

Assets

$296.87 million

$296,870,000.00

Total Shares Outstanding

29.00 million

29,000,000

Average Daily Trading Volume

$202.31 Thousand

$202,308.72

Sector

Health Care

Industry

Biotechnology

ENTA

ENTA revenue and profits

Financial Results ENTA

DRAG THE FRAME TO SEE MORE DATA

ENTA cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Enanta Pharmaceuticals (ENTA) today?

A cotação de Enanta Pharmaceuticals (ENTA) hoje está em US$ 13.51, com uma variação de 61.03% em relação ao último ano. A cotação de Enanta Pharmaceuticals (ENTA) iniciou o ano negociando na casa dos US$ 15.77 e hoje está em US$ 13.51. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Enanta Pharmaceuticals (ENTA) e dados de ações do Ibovespa e mercados internacionais.

Quando Enanta Pharmaceuticals (ENTA) paga dividendos?

Enanta Pharmaceuticals (ENTA) não distribuiu dividendos no último ano.

Is Enanta Pharmaceuticals (ENTA) a good investment?

Atualmente, Enanta Pharmaceuticals (ENTA) está cotada a US$ 13.51, com um P/L de -5.95, representando um desvio de -462% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 61.03 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 61.03%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Enanta Pharmaceuticals (ENTA) stock?

Investir em ações de Enanta Pharmaceuticals (ENTA) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Enanta Pharmaceuticals (ENTA) yield today?

A rentabilidade de Enanta Pharmaceuticals (ENTA) foi de 0.00% no último mês, 61.03% no último ano e -73.67% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Enanta Pharmaceuticals (ENTA) hoje, o investimento total seria de US$ 1,351.00, com base na cotação atual de US$ 13.51.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 2,175.52
Em 5 anos: US$ 355.72
Em 10 anos: US$ 769.80

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ENTA

Enanta Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ENTA

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING ENTA WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Enanta Pharmaceuticals

Enanta Pharmaceuticals Inc.

United States

31 years

2013

141

PROFIT X PRICE ENTA

Financial Results ENTA

ENTA cash flow

Asset, Revenue and Profit Growth - ENTA

ENTA balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions